Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 37pembrolizumab 30cabozantinib 27Specimen Handling 25Magnetic Resonance Spectroscopy 22Ipilimumab 20lenvatinib 16Axitinib 15belzutifan 13CTLA-4 Antigen 10Sunitinib 9Biopsy 9Radiosurgery 8atezolizumab 7Immunoglobulin G 5toripalimab 4fludarabine 4avelumab 4aldesleukin 4Everolimus 4Disulfides 4Cyclophosphamide 4zimberelimab 3tivozanib 3spartalizumab 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × sodium-iodide symporter × 90 days × Clear all
NCT07510334 2026-04-03

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Mayo Clinic

Phase 2 Not yet recruiting
18 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡